Drugs / LY4337713
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07213791 | Oct 2025 → Jul 2028 expected | breast neoplasm, cholangiocarcinoma, colorectal neoplasm, gastric neoplasm +3 | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4337713 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213791 ↗ |
| Modality | Other / unclassified | “Radioligand Therapy With LY4337713” NCT07213791 ↗ |
| Route | Intravenous | “Administered IV.” NCT07213791 ↗ |